China National Medicines (Genertec, 600056) Acquires 70% Equity in HQ Pharma for RMB 525 Million, with MedBio Capital as Exclusive Financial Advisor to the Sellers

2025-12-31 08:00:00

China National Medicines (Genertec, 600056) Acquires 70% Equity in HQ Pharma for RMB 525 Million, with MedBio Capital as Exclusive Financial Advisor to the Sellers, cover image

On the evening of December 30, 2025, China National Medicines (600056) announced that the company had entered into a Share Purchase Agreement regarding Shanghai Zezheng Pharmaceutical Technology Co., Ltd. with 13 counterparties—He Dunwei, Wu Dong, Wankang Healthcare Co., Ltd., Zhang Wei, Jiaxing Renhe Jiarui Equity Investment Partnership (Limited Partnership), Yang Zhenyu, Xinyu Renhe Ruiyun Investment Partnership (Limited Partnership), Tang Xudong, Xinyu Renhe Chunrun Investment Partnership (Limited Partnership), Yantai Guoxin Zezheng Equity Investment Partnership (Limited Partnership), Wang Qinghan, Changzhou Binfu Yinaiersheng Venture Capital Partnership (Limited Partnership) and Zhang Qing—to acquire, for a cash consideration of RMB 525 million, a 70% equity interest in Shanghai Zezheng Pharmaceutical Technology Co., Ltd. (hereinafter “HQ Pharma”) held in aggregate by the counterparties.

MedBio Capital acted as exclusive financial advisor to the sellers.

Founded in 2017, HQ Pharma is a pharmaceutical R&D company specializing in improved new drugs and complex formulations, and can provide full-process R&D services covering pharmaceutical research, clinical trials and regulatory filings.

HQ Pharma has established a business model of providing R&D services to customers and translating the results of its own R&D technology rights. Its R&D services can be divided into pharmaceutical research and clinical research.

It currently has laboratories and offices in Shanghai, Jinan in Shandong and Zibo in Shandong, and has deployed clinical operations, regulatory and marketing teams in a number of locations worldwide.

HQ Pharma now has several technology platforms for the R&D of complex formulations, including a pediatric drug technology platform, an oral sustained- and controlled-release platform, a complex injectable technology platform and a drug-device combination technology platform.

HQ Pharma has for many years been rooted in pharmaceutical R&D. Its R&D and management teams are experienced and relatively stable. Drawing on independently mastered core technologies, it has built multiple R&D service platforms, and the customers it serves include a number of large pharmaceutical companies. From HQ Pharma’s establishment through the issuance date of the valuation report, HQ Pharma has led or participated in the R&D of a number of generic and improved new drug projects, and has successfully filed more than 100 R&D service projects with China’s National Medical Products Administration, of which 55 have obtained marketing approval (including 23 generic consistency-evaluation products, 17 generic drugs, 1 Category 2 improved new drug, 1 U.S. FDA-approved generic, and 13 other clinical-only products), and 8 have obtained clinical trial approvals.

Building on a number of core technologies, and in addition to providing R&D services to customers, HQ Pharma has independently initiated and laid out R&D programs in improved new drugs, first generics and complex formulations.

Based on the foregoing, HQ Pharma’s businesses enjoy relatively strong competitive advantages in pharmaceutical R&D and CRO services, and the results of an income-approach valuation can more reasonably reflect the company’s value as of the valuation benchmark date.

China National Medicines stated that, drawing on years of R&D experience, HQ Pharma has established independent R&D platforms in generics, improved new drugs, active pharmaceutical ingredients and innovative drugs, and has certain advantages in R&D cost, R&D efficiency and patent layout, with the relevant technologies already applied in a number of R&D projects.

Through this transaction, the company will enhance its overall capabilities in pharmaceutical R&D and innovation, address shortcomings in its current R&D system, promote in-depth integration of the two sides in technology, markets and resources, deepen its presence across generic drug research, improved new drug research and innovative drug research, and connect the entire industry chain from R&D to manufacturing, thereby building an industrial layout in which pharmaceutical R&D, pharmaceutical manufacturing and pharmaceutical distribution develop in concert, which will help further enhance the listed company’s competitiveness.

About MedBio Capital

MedBio Capital is a boutique investment bank focused on life sciences and healthcare, committed to serving as a capital and strategic partner to leading scientists and entrepreneurs. Its core team has worked in the healthcare industry for many years, covering key stages in R&D, clinical development and the market, and brings combined experience in investment, investment banking and consulting. Team members have collectively completed more than RMB 10 billion in financing transactions and have served more than a dozen leading listed healthcare companies.

This article was adapted from the MedBio Capital WeChat official account.